REVB · Revelation Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| James Rolke Chief Executive Officer | ▲ Buy | Grant | 422,814 Shares held | 8/17/2026 | View profile |
| GLAZER CAPITAL, LLC 10% Owner | ▼ Sell | Open Market | 381,106 Shares held | 9/23/2021 | View profile |
| Chester Stanley Zygmont III Chief Financial Officer | ▼ Sell | Gift | 300,136 Shares held | 8/17/2026 | View profile |
| Jess Roper | ▲ Buy | Grant | 44,839 Shares held | 8/17/2026 | View profile |
| Jennifer Carver | ▲ Buy | Grant | 44,769 Shares held | 8/17/2026 | View profile |
| Lakhmir S. Chawla | ▲ Buy | Grant | 44,169 Shares held | 8/17/2026 | View profile |
| George F. Tidmarsh Director | ▲ Buy | Grant | 268 Shares held | 2/11/2025 | View profile |
| Lawrence Feis | ▼ Sell | Other | 0 Shares held | 1/10/2022 | View profile |
Transaction History
| Jess Roper | ▲ Buy | Grant | 32,011 | $0 | 8/17/2026 |
| Chester Stanley Zygmont III | ▼ Sell | Gift | 208,073 | $0 | 8/17/2026 |
| Lakhmir S. Chawla | ▲ Buy | Grant | 32,011 | $0 | 8/17/2026 |
| Chester Stanley Zygmont III | ▼ Sell | Gift | 208,073 | $0 | 8/17/2026 |
| James Rolke | ▲ Buy | Grant | 208,076 | $0 | 8/17/2026 |
| Chester Stanley Zygmont III | ▲ Buy | Grant | 208,073 | $0 | 8/17/2026 |
| Jennifer Carver | ▲ Buy | Grant | 32,011 | $0 | 8/17/2026 |
| James Rolke | ▼ Sell | Tax Withholding | 10,115 | $11K | 4/30/2026 |
| Chester Stanley Zygmont III | ▼ Sell | Tax Withholding | 13,285 | $15K | 4/30/2026 |
| Chester Stanley Zygmont III | ▼ Sell | Tax Withholding | 13,100 | $22K | 2/4/2026 |
| Jess Roper | ▼ Sell | Tax Withholding | 1,591 | $3K | 2/3/2026 |
| Lakhmir S. Chawla | ▼ Sell | Tax Withholding | 2,261 | $4K | 2/3/2026 |
| Jennifer Carver | ▼ Sell | Tax Withholding | 1,661 | $3K | 2/3/2026 |
| James Rolke | ▼ Sell | Tax Withholding | 8,521 | $16K | 2/3/2026 |
| James Rolke | ▲ Buy | Grant | 532,829 | $480K | 1/8/2026 |
| Chester Stanley Zygmont III | ▲ Buy | Grant | 78,145 | $70K | 1/8/2026 |
| Jennifer Carver | ▲ Buy | Grant | 41,981 | $38K | 1/8/2026 |
| Jess Roper | ▲ Buy | Grant | 41,981 | $38K | 1/8/2026 |
| Lakhmir S. Chawla | ▲ Buy | Grant | 41,981 | $38K | 1/8/2026 |
| Lakhmir S. Chawla | ▲ Buy | Grant | 15,625 | $20K | 10/29/2025 |
| James Rolke | ▲ Buy | Grant | 390,614 | $500K | 10/29/2025 |
| Jennifer Carver | ▲ Buy | Grant | 15,625 | $20K | 10/29/2025 |
| Chester Stanley Zygmont III | ▲ Buy | Grant | 390,614 | $500K | 10/29/2025 |
| Jess Roper | ▲ Buy | Grant | 15,625 | $20K | 10/29/2025 |
| Lakhmir S. Chawla | ▲ Buy | Grant | 181 | $700 | 2/11/2025 |
| Jennifer Carver | ▲ Buy | Grant | 181 | $700 | 2/11/2025 |
| Jess Roper | ▲ Buy | Grant | 181 | $700 | 2/11/2025 |
| James Rolke | ▲ Buy | Grant | 30,095 | $116K | 2/11/2025 |
| Chester Stanley Zygmont III | ▲ Buy | Grant | 15,048 | $58K | 2/11/2025 |
| George F. Tidmarsh | ▲ Buy | Grant | 181 | $700 | 2/11/2025 |
| George F. Tidmarsh | ▼ Sell | Open Market | 27,771 | $14K | 12/8/2023 |
| George F. Tidmarsh | ▼ Sell | Open Market | 1,845 | $1K | 10/16/2023 |
| George F. Tidmarsh | ▼ Sell | Open Market | 10,957 | $7K | 10/16/2023 |
| George F. Tidmarsh | ▼ Sell | Open Market | 1,429 | $986 | 9/28/2023 |
| George F. Tidmarsh | ▼ Sell | Open Market | 4,000 | $3K | 9/18/2023 |
| George F. Tidmarsh | ▼ Sell | Open Market | 9,500 | $7K | 9/15/2023 |
| George F. Tidmarsh | ▼ Sell | Open Market | 12,000 | $9K | 9/14/2023 |
| George F. Tidmarsh | ▲ Buy | Open Market | 25,000 | $29K | 4/18/2023 |
| George F. Tidmarsh | ▲ Buy | Open Market | 26,500 | $31K | 4/17/2023 |
| George F. Tidmarsh | ▲ Buy | Open Market | 20,000 | $32K | 2/25/2022 |
| George F. Tidmarsh | ▲ Buy | Open Market | 30,000 | $77K | 2/9/2022 |
| George F. Tidmarsh | ▲ Buy | Open Market | 1,000 | $3K | 2/8/2022 |
| George F. Tidmarsh | ▲ Buy | Open Market | 42,100 | $110K | 2/7/2022 |
| George F. Tidmarsh | ▲ Buy | Open Market | 7,900 | $18K | 2/4/2022 |
| Lawrence Feis | ▼ Sell | Other | 731,950 | $7.5M | 1/10/2022 |
| GLAZER CAPITAL, LLC | ▼ Sell | Open Market | 611,541 | $6.2M | 9/23/2021 |
| GLAZER CAPITAL, LLC | ▼ Sell | Open Market | 5 | $50 | 9/22/2021 |
| GLAZER CAPITAL, LLC | ▼ Sell | Open Market | 43,000 | $433K | 9/21/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
REVB announces 1-for-7 reverse stock split effective Oct 20
Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.
REVB announces 1-for-7 reverse stock split effective Oct 20. Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.